Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: TLK286
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2004-07-30

Last Posted Date: 2012-05-31

Lead Sponsor: Telik

Target Recruit Count: 100

Registration Number: NCT00088556

Locations: 🇺🇸
East Bay Medical Oncology/Hematology Associates, Concord, California, United States
🇺🇸
Bay Area Cancer Research Group, Concord, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 24 locations

Chemotherapy in Treating Patients With Retinoblastoma

Phase 2

Completed

Conditions: Retinoblastoma

First Posted Date: 2004-07-29

Last Posted Date: 2013-06-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 50

Registration Number: NCT00002675

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Phase 1

Conditions: Breast Cancer

First Posted Date: 2004-07-29

Last Posted Date: 2014-01-10

Lead Sponsor: St. Louis University

Target Recruit Count: 30

Registration Number: NCT00002627

Locations: 🇺🇸
St. Louis University Health Sciences Center, Saint Louis, Missouri, United States

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-07-26

Last Posted Date: 2012-07-02

Lead Sponsor: Northwestern University

Registration Number: NCT00004169

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: etoposide
Drug: paclitaxel
Drug: topotecan hydrochloride
Radiation: radiation therapy

First Posted Date: 2004-07-22

Last Posted Date: 2016-07-20

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 75

Registration Number: NCT00003812

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States

and more 45 locations

High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-22

Last Posted Date: 2012-02-22

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 61

Registration Number: NCT00003392

Locations: 🇺🇸
Bone Marrow Stem Cell Transplant Institute of Florida, Fort Lauderdale, Florida, United States
🇺🇸
Lutheran General Cancer Care Center, Park Ridge, Illinois, United States
🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

and more 11 locations

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer

First Posted Date: 2004-07-21

Last Posted Date: 2008-12-04

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 86

Registration Number: NCT00088088

Locations: 🇺🇸
Cancer Institute Medical Group, Santa Monica, California, United States
🇺🇸
Oncology Hematology Consultants, Sarasota, Florida, United States
🇺🇸
Overton Brooks, VAMC, Shreveport, Louisiana, United States

and more 16 locations

Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-07-19

Last Posted Date: 2013-06-21

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00003881

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Veterans Affairs Medical Center - Cleveland, Cleveland, Ohio, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

and more 68 locations

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2004-07-19

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00005806

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-16

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00003877

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy